


Status: Currently Official on 16-Feb-2025
 Official Date: Official as of 01-Nov-2020
 Document Type: USP Monographs
 DocId: GUID-C1E3DF2E-B4DA-4A71-9D65-176ADDD3F5FD_3_en-US
 DOI: https://doi.org/10.31003/USPNF_M6130_03_01
 DOI Ref: 8b8dj

© 2025 USPC
 Do not distribute

Pregabalin



$C_8H_{17}NO_2$ 159.23

(S)-3-(Aminomethyl)-5-methylhexanoic acid CAS RN®: 148553-50-8.

DEFINITION

Pregabalin contains NLT 98.0% and NMT 102.0% of pregabalin ($C_8H_{17}NO_2$), calculated on the dried basis.

IDENTIFICATION

Change to read:

- **A.** [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy](#): (197K)▲ or (197A)▲ (USP 1-Aug-2020)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Mobile phase: [Acetonitrile](#) and [water](#) (5:95)

Standard solution: 2.0 mg/mL of [USP Pregabalin RS](#) in *Mobile phase*

Sample solution: 2.0 mg/mL of Pregabalin in *Mobile phase*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 205 nm

Column: 4.6-mm × 25-cm; 5-μm packing [L1](#)

Temperatures

Autosampler: 10°

Column: 25°

Flow rate: 1.0 mL/min

Injection volume: 20 μL

Run time: NLT 2.5 times the retention time of pregabalin

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 1.5

Relative standard deviation: NMT 0.73%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of pregabalin ($C_8H_{17}NO_2$) in the portion of Pregabalin taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of pregabalin from the *Sample solution*

r_S = peak response of pregabalin from the *Standard solution*

C_s = concentration of [USP Pregabalin RS](#) in the *Standard solution* (mg/mL)

C_u = concentration of Pregabalin in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the dried basis

IMPURITIES

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

Change to read:

- [CHLORIDE AND SULFATE \(221\)](#), *Chloride*

Standard solution: Prepare as directed in the chapter using ▲1.4 mL.▲ (USP 1-Aug-2020)

Sample solution: Prepare as directed in the chapter using ▲1.0 g▲ (USP 1-Aug-2020) of Pregabalin.

Acceptance criteria: The turbidity produced in the *Sample solution* is NMT that produced in the *Standard solution* (0.1%).

Change to read:

- **ORGANIC IMPURITIES**

Buffer: 0.04 M [dibasic ammonium phosphate](#). Adjust with [phosphoric acid](#) to a pH of 6.5.

Solution A: [Methanol](#) and *Buffer* (20:80)

Solution B: [Methanol](#) and [acetonitrile](#) (10:90)

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	98	2
5	98	2
16	80	20
33	80	20
34	98	2
45	98	2

▲**Sensitivity solution:** 0.005 mg/mL of [USP Pregabalin RS](#) in [water](#)▲ (USP 1-Aug-2020)

Standard solution: 0.01 mg/mL of [USP Mandelic Acid RS](#) and 0.05 mg/mL each of [USP Pregabalin RS](#) and [USP Pregabalin Related Compound C RS](#) in [water](#)

Sample solution: 10.0 mg/mL of Pregabalin in [water](#)

Chromatographic system

(See [Chromatography \(621\)](#), *System Suitability*.)

Mode: LC

Detector: UV 210 nm

Column: 4.6-mm × 25-cm; 5-μm packing [L1](#)

Column temperature: 35°

Flow rate: 1.0 mL/min

Injection volume: 20 μL

System suitability

Samples: ▲*Sensitivity solution* and ▲ (USP 1-Aug-2020) *Standard solution*

Suitability requirements

Relative standard deviation: NMT 5% for mandelic acid, pregabalin, and pregabalin related compound C, ▲*Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*▲ (USP 1-Aug-2020)

Analysis

Samples: *Standard solution* and *Sample solution*